oral and rheumatoid arthritis (RA) Archives

Abstract Number: 10L • ACR/ARHP Annual Meeting 2017
Upadacitinib (ABT-494) in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological Dmards: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of a Selective JAK-1 Inhibitor
Mark C. Genovese¹, Roy Fleischmann², Bernard Combe³, Stephen Hall⁴, Ying Zhang⁵, Yijie Zhou⁵, Mohamed-Eslam F. Mohamed⁶, Sebastian Meerwein⁷ and Aileen L. Pangan⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ³Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ⁴Department of Medicine, Monash University, Cabrini Health and Emeritus Research, Malvern, Australia, ⁵AbbVie Inc., North Chicago, IL, ⁶Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co, Ludwigshafen, Germany

Background/Purpose: Upadacitinib (ABT-494, UPA), an oral, selective JAK-1 inhibitor was effective in 2 ph2 trials in rheumatoid arthritis (RA) pts with inadequate response (IR)/intolerance to…
Abstract Number: 491 • ACR/ARHP Annual Meeting 2017
Streptococcus Species Enriched in the Oral Cavity of RA Patients: A Persistent Source of Peptidoglycan-Polysaccharide Polymers Which Drive Disseminated Synovial Inflammation
Rabia Moentadj¹, Linda Rehaume², Paraic O Cuiv³, Kate Ormerod⁴, Muralidhara Maradana³, Vanessa Anne Lakis³, Mark Morrison², Philip Hugenholtz⁴, Helen Benham⁵, Kim-Anh Lê Cao⁶ and Ranjeny Thomas¹, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, ³The University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Australia, ⁵The University of Queensland Faculty of Medicine, Brisbane, Australia, ⁶School of Mathematics and Statistics, Centre for Systems Genomics, The University of Melbourne, Melbourne, Australia
Background/Purpose: In Rheumatoid Arthritis (RA), genetic predisposition and environmental risk factors promote dysbiosis of oral and fecal microbiota. We hypothesized that specific microbial taxa (operational…
Abstract Number: 1046 • ACR/ARHP Annual Meeting 2015
Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors
Mark C. Genovese¹, Joel M. Kremer², Cynthia Kartman³, Douglas E. Schlichting³, Li Xie³, Tara Carmack⁴, William L. Macias³ and Josef S. Smolen⁵, ¹Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Center for Rheumatology, Albany, NY, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Durham, NC, ⁵Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib, an oral inhibitor of JAK1/JAK2, improved disease activity with an acceptable safety profile in a phase 3 study (RA-BEACON) of patients with active…

Abstracts tagged "oral and rheumatoid arthritis (RA)"

Upadacitinib (ABT-494) in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological Dmards: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of a Selective JAK-1 Inhibitor

Streptococcus Species Enriched in the Oral Cavity of RA Patients: A Persistent Source of Peptidoglycan-Polysaccharide Polymers Which Drive Disseminated Synovial Inflammation

Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors